IDO1 and neoplasm: Interestingly, pharmacologic blockade of IDO leads to enhanced IL-6 production by pDC that converts tolerogenic CD4+ Tregs into TH17-like cells, and this conversion correlates with enhanced CD8+ T cell activation and anti-tumor immunity (131).